Brief Report
Volume 10: 01, 2025

Journal of Oncology Medicine & Practice

ISSN: 2576-3857

Open Access

The Role of Brachytherapy in Modern Oncology

Shamsi Haider*

Department of Nuclear Medicine, Technische Universität München, 81675 Munich, Germany

Introduction

Brachytherapy, a form of internal radiation therapy, has established itself as a crucial treatment modality in modern oncology. With its capacity to deliver targeted doses of radiation to tumors with precision, it has become a cornerstone in the management of various malignancies, including prostate, gynecological, breast, and other cancers. The technique involves placing radioactive sources directly inside or very close to the tumor, allowing for high doses of radiation to be administered while minimizing damage to surrounding healthy tissues. This highly localized approach provides distinct advantages over External Beam Radiation Therapy (EBRT), including greater precision, reduced treatment time, and fewer side effects, all of which contribute to its growing role in contemporary cancer care.

Description

The origins of brachytherapy date back to the early 20th century and its evolution have been driven by advancements in radiation physics, imaging technologies, and medical devices. Initially, the technique was limited to certain types of cancers, but with technological innovations, it has expanded to include a broader range of malignancies. One of the significant developments that have enhanced the precision and efficacy of brachytherapy is the integration of imaging modalities such as ultrasound, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI). These imaging tools have enabled clinicians to better visualize the tumour's location, size, and shape, facilitating more accurate placement of radioactive sources. This improvement in targeting has led to more effective treatments with fewer complications and better outcomes for patients [1].

Prostate cancer is one of the most common malignancies treated with brachytherapy. In fact, for localized prostate cancer, brachytherapy has become a standard treatment option. The procedure involves implanting small radioactive seeds into the prostate gland, where they emit radiation over a period of time. The precise placement of these seeds allows for a high dose of radiation to be delivered directly to the prostate tumor while sparing surrounding tissues, such as the bladder and rectum. For many patients, brachytherapy is an attractive option because it typically involves fewer treatments compared to external radiation therapy and has a relatively short recovery time. Moreover, studies have shown that the long-term outcomes of brachytherapy for prostate cancer, including survival rates and disease recurrence, are comparable to other treatment modalities like surgery and external beam radiation [2].

Another area where brachytherapy has proven beneficial is in the treatment of gynecological cancers, particularly those of the cervix and endometrium. Cervical cancer, often diagnosed at an advanced stage, has historically been associated with poor prognosis. However, brachytherapy has significantly improved the treatment outcomes for patients with this disease. The method of administering brachytherapy for cervical cancer typically involves placing a radioactive source inside the cervical tumor, delivering a high dose of radiation directly to the cancerous tissue while minimizing exposure to nearby organs. For patients with advanced cervical cancer, brachytherapy is often used in conjunction with external beam radiation and chemotherapy as part of a multimodal treatment approach. The combination of these therapies has been shown to improve survival rates and reduce the risk of recurrence [3].

Brachytherapy also plays a critical role in breast cancer management, particularly for patients who undergo breast-conserving surgery. After a tumor is removed, radiation therapy is typically used to eliminate any remaining cancer cells in the breast tissue. While external beam radiation has been the traditional approach, brachytherapy has emerged as an alternative for some patients. In this case, a small radioactive source is placed directly into the breast tissue at the site of the tumor cavity. This technique, often referred to as partial breast irradiation, offers the advantage of delivering a higher radiation dose to the target area in a shorter period, typically over a course of five days, compared to the six to seven weeks required for traditional whole-breast radiation [4,5].

In addition to its role in specific cancer types, brachytherapy is increasingly being used in the treatment of other malignancies, such as head and neck cancers, skin cancers, and esophageal cancer. The ability to deliver radiation directly to the tumor site makes brachytherapy an ideal treatment for tumors located in areas that are difficult to treat with external radiation. For example, in head and neck cancers, where tumors may be located near critical structures such as the spinal cord, nerves, and major blood vessels, brachytherapy provides a means of delivering high-dose radiation without jeopardizing surrounding healthy tissue. Similarly, in skin cancers, particularly basal cell carcinoma and squamous cell carcinoma, brachytherapy offers a non-invasive option for delivering targeted radiation therapy to superficial tumors.

A key advantage of brachytherapy is its ability to deliver radiation with high precision, which significantly reduces the risk of damage to adjacent healthy tissues. This feature is particularly important for cancers that are located near vital organs or structures, such as the brain, lungs, or liver. For example, in the treatment of liver cancer, where tumors are often located near large blood vessels and the liver itself, brachytherapy allows for precise targeting of the tumor while minimizing damage to the surrounding liver tissue. This precise targeting not only improves the efficacy of the treatment but also reduces the likelihood of severe side effects, such as radiation burns, fibrosis, and tissue necrosis, which can occur with external beam radiation.

Conclusion

In conclusion, brachytherapy has become an integral component of modern oncology, offering a targeted, effective, and minimally invasive approach to cancer treatment. Its ability to deliver high doses of radiation to tumors while minimizing damage to surrounding healthy tissue makes it a valuable tool in the management of a wide range of cancers. With continued advancements in imaging technology, treatment planning, and radioactive isotopes, brachytherapy's role in cancer care is likely to expand, providing even more patients with the opportunity for successful outcomes and improved quality of life. As a result, brachytherapy remains an essential option in the arsenal of treatments available to oncologists in the fight against cancer.

Acknowledgement

None.

***Address for Correspondence:** Shamsi Haider, Department of Nuclear Medicine, Technische Universität München, 81675 Munich, Germany, E-mail: shamsihaider@gmail.com*

Received: 01 February, 2025, Manuscript No. jomp-25-162948; **Editor assigned:** 03 February, 2025, PreQC No. P-162948; **Reviewed:** 14 February, 2025, QC No. Q-162948; **Revised:** 19 February, 2025, Manuscript No. R-162948; **Published**: 26 February, 2025, DOI: 10.37421/2576-3857.2025.10.287

Conflict of Interest

No potential conflict of interest was reported by the authors.

References

1. Britten, Carolyn D. "PI3K and MEK inhibitor combinations: Examining the evidence in selected tumor types." *Cancer Chemother Pharmacol* 71 (2013): 1395-1409.
2. Kolesnik, D. L., O. N. Pyaskovskaya, Yu R. Yakshibaeva and G. I. Solyanik. "Time-dependent cytotoxicity of dichloroacetate and metformin against Lewis lung carcinoma." *Exp Oncol* 41 (2019): 14-19.
3. Feuerecker, Benedikt, Christof Seidl, Sabine Pirsig and Gernot Bruchelt, et al. "DCA promotes progression of neuroblastoma tumors in nude mice." *Am J Cancer Res* 5 (2015): 812.
4. Serrao, Eva M. and Kevin M. Brindle. "Dynamic nuclear polarisation: The future of imaging in oncology?." *Porto Biomed J* 2 (2017): 71-75.
5. Michelakis, E. D., G. Sutendra, P. Dromparis and L. Webster, et al. "Metabolic modulation of glioblastoma with dichloroacetate." *Sci Transl Med* 2 (2010): 31ra34-31ra34.

How to cite this article: Haider, Shamsi. "The Role of Brachytherapy in Modern Oncology." *J Oncol Med & Pract* 10 (2025): 287.